Viral infections:

Indications for: VEKLURY

COVID-19 in patients requiring hospitalization.

Adult Dosage:

Give by IV infusion over 30–120mins. ≥12yrs (≥40kg): Initially 200mg once on Day 1, followed by 100mg once daily from Day 2. Patients not requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO): treat for 5 days; if no improvement, may extend for a total duration of 10 days. Patients requiring invasive mechanical ventilation and/or ECMO: treat for 10 days.

Children Dosage:

<12yrs or <40kg: not established.

VEKLURY Warnings/Precautions:

Should only be administered in a hospital or in a healthcare setting providing acute care. Obtain eGFR, hepatic tests, and prothrombin time prior to initiation and monitor during treatment. Consider discontinuing if ALT levels increase to >10×ULN. Discontinue if ALT elevation is accompanied by signs/symptoms of liver inflammation. Monitor closely for hypersensitivity reactions during and following therapy; discontinue immediately if significant reactions occur. Renal impairment (eGFR <30mL/min): not recommended. Hepatic impairment. Elderly (monitor). Pregnancy. Nursing mothers.

VEKLURY Classification:

SARS-CoV-2 nucleotide analogue RNA polymerase inhibitor.

VEKLURY Interactions:

Do not administer the diluted solution simultaneously with any other medication. Concomitant chloroquine phosphate or hydroxychloroquine sulfate: not recommended.

Adverse Reactions:

Nausea, increased ALT/AST; hypersensitivity reactions, generalized seizure, rash.

Generic Drug Availability:


How Supplied:

Single-dose vial—1

Pricing for VEKLURY

100mg of 5mg/ml vial (Qty: 1)
Appx. price $540